Moreover, it was demonstrated that suppression of ADAM17 has the potency to become a NK cell based immunotherapy in cancer via enhancing the purity of extended NK cells and increasing antibody dependent cellular cytotoxicity (ADCC) against trastuzumab in the cell lines of BC [70]. This evidence concerns the gene ADAM17 and breast cancer.